149 related articles for article (PubMed ID: 9039622)
1. Dynamic 3D-MR mammography: is there a benefit of sophisticated evaluation of enhancement curves for clinical routine?
Müller-Schimpfle M; Ohmenhäuser K; Sand J; Stoll P; Claussen CD
J Magn Reson Imaging; 1997; 7(1):236-40. PubMed ID: 9039622
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma.
Mussurakis S; Buckley DL; Bowsley SJ; Carleton PJ; Fox JN; Turnbull LW; Horsman A
Invest Radiol; 1995 Nov; 30(11):650-62. PubMed ID: 8557506
[TBL] [Abstract][Full Text] [Related]
3. [A pharmacokinetic analysis of Gd-DTPA enhancement in MRT in breast carcinoma].
Hess T; Knopp MV; Hoffmann U; Brix G; Junkermann H; Zuna I; von Fournier D; van Kaick G
Rofo; 1994 Jun; 160(6):518-23. PubMed ID: 8011997
[TBL] [Abstract][Full Text] [Related]
4. Dynamic MR mammography: a technique for potentially reducing the biopsy rate for benign breast disease.
Turkat TJ; Klein BD; Polan RL; Richman RH
J Magn Reson Imaging; 1994; 4(4):563-8. PubMed ID: 7949682
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions.
Boné B; Péntek Z; Perbeck L; Veress B
Acta Radiol; 1997 Jul; 38(4 Pt 1):489-96. PubMed ID: 9240665
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
[TBL] [Abstract][Full Text] [Related]
7. Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Hawighorst H; Knapstein PG; Schaeffer U; Knopp MV; Brix G; Hoffmann U; Zuna I; Essig M; van Kaick G
AJR Am J Roentgenol; 1996 Feb; 166(2):401-8. PubMed ID: 8553955
[TBL] [Abstract][Full Text] [Related]
8. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features.
Stomper PC; Herman S; Klippenstein DL; Winston JS; Edge SB; Arredondo MA; Mazurchuk RV; Blumenson LE
Radiology; 1995 Nov; 197(2):387-95. PubMed ID: 7480682
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions.
den Boer JA; Hoenderop RK; Smink J; Dornseiffen G; Koch PW; Mulder JH; Slump CH; Volker ED; de Vos RA
J Magn Reson Imaging; 1997; 7(4):702-15. PubMed ID: 9243392
[TBL] [Abstract][Full Text] [Related]
10. MR imaging of the breast with Gd-DTPA enhancement: comparison with mammography and ultrasonography.
Hachiya J; Seki T; Okada M; Nitatori T; Korenaga T; Furuya Y
Radiat Med; 1991; 9(6):232-40. PubMed ID: 1668410
[TBL] [Abstract][Full Text] [Related]
11. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours.
Mussurakis S; Buckley DL; Drew PJ; Fox JN; Carleton PJ; Turnbull LW; Horsman A
Clin Radiol; 1997 Jul; 52(7):516-26. PubMed ID: 9240704
[TBL] [Abstract][Full Text] [Related]
12. Do mammography, sonography, and MR mammography have a diagnostic benefit compared with mammography and sonography?
Müller-Schimpfle M; Stoll P; Stern W; Kurz S; Dammann F; Claussen CD
AJR Am J Roentgenol; 1997 May; 168(5):1323-9. PubMed ID: 9129436
[TBL] [Abstract][Full Text] [Related]
13. [MR mammography at 0.5 tesla. II. The capacity to differentiate malignant and benign lesions in MR mammography at 0.5 and 1.5 T].
Kuhl CK; Kreft BP; Hauswirth A; Gieseke J; Elevelt A; Reiser M; Schild HH
Rofo; 1995 Jun; 162(6):482-91. PubMed ID: 7605960
[TBL] [Abstract][Full Text] [Related]
14. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique.
Boetes C; Barentsz JO; Mus RD; van der Sluis RF; van Erning LJ; Hendriks JH; Holland R; Ruys SH
Radiology; 1994 Dec; 193(3):777-81. PubMed ID: 7972823
[TBL] [Abstract][Full Text] [Related]
15. Breast disease: tissue characterization with Gd-DTPA enhancement profiles.
Stack JP; Redmond OM; Codd MB; Dervan PA; Ennis JT
Radiology; 1990 Feb; 174(2):491-4. PubMed ID: 2296657
[TBL] [Abstract][Full Text] [Related]
16. MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma.
Rieber A; Merkle E; Böhm W; Brambs HJ; Tomczak R
J Comput Assist Tomogr; 1997; 21(5):773-9. PubMed ID: 9294574
[TBL] [Abstract][Full Text] [Related]
17. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography.
Gribbestad IS; Nilsen G; Fjøsne HE; Kvinnsland S; Haugen OA; Rinck PA
J Magn Reson Imaging; 1994; 4(3):477-80. PubMed ID: 8061451
[TBL] [Abstract][Full Text] [Related]
18. Breast MR imaging with commercially available techniques: radiologic-pathologic correlation.
Fobben ES; Rubin CZ; Kalisher L; Dembner AG; Seltzer MH; Santoro EJ
Radiology; 1995 Jul; 196(1):143-52. PubMed ID: 7784558
[TBL] [Abstract][Full Text] [Related]
19. Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived variables for breast lesions in dynamic, contrast-enhanced MR mammography.
Hauth EA; Jaeger HJ; Maderwald S; Muehler A; Kimmig R; Forsting M
Eur J Radiol; 2008 May; 66(2):300-8. PubMed ID: 17658235
[TBL] [Abstract][Full Text] [Related]
20. Computed model of gadolinium enhanced MRI of breast disease.
Kenney PJ; Sobol WT; Smith JK; Morgan DE
Eur J Radiol; 1997 Feb; 24(2):109-19. PubMed ID: 9097052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
